Skip to main content

Financing Biomedical Research



Since I commented briefly on the pseudo-science of the anti-vaccine folks Sunday, I thought I would stay on a biomedical kick today, and perhaps tomorrow. Though the subject of today's post is, aside from the applicability of that broad label, very different from Sunday's. As for tomorrow ... tomorrow only knows.

Today, I'm looking at an article by Jose-Maria Fernandez, Roger M. Stein, and Andrew W. Lo, "Commercializing Biomedical Research Through Securitization Techniques." You can access it here.  
The idea is that biomedical innovation is getting more expensive and riskier. Upon whom shall that risk fall? Well, securitization is the obvious method of spreading the risk around, although the word "securitization" acquired rather a bad odor from its connection with the pre-2007 housing market.
 
Anyway, the authors are undaunted by that odor. They propose securitizing megafunds of $5 to $15 billion that could yield a floor of 8.9% for equity investors.
 
The debt holders, holding something the authors dub "research backed obligations," would make less than the equity holders, as is typical. Still, they would get between 5% and 8% according to a "simulation using historical data for new molecular entities in oncology from 1990 to 2011."
 
The beaming fellow above is Andrew Lo. I tried to copy the author's diagram of the waterfall/schematic for their proposed structure, but somehow it wouldn't paste onto here.
 
I wish them well, of course. Anything that gets market-oriented funding to real scientists weakens the pseudo sort.
 
Go, Lo!
 
 


 
Labels:

Comments

Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.   We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a maj...
9 comments
Read more

Searle: The Chinese Room

John Searle has become the object of accusations of improper conduct. These accusations even have some people in the world of academic philosophy saying that instructors in that world should try to avoid teaching Searle's views. That is an odd contention, and has given rise to heated exchanges in certain corners of the blogosphere.  At Leiter Reports, I encountered a comment from someone describing himself as "grad student drop out." GSDO said: " This is a side question (and not at all an attempt to answer the question BL posed): How important is John Searle's work? Are people still working on speech act theory or is that just another dead end in the history of 20th century philosophy? My impression is that his reputation is somewhat inflated from all of his speaking engagements and NYRoB reviews. The Chinese room argument is a classic, but is there much more to his work than that?" I took it upon myself to answer that on LR. But here I'll tak...
17 comments
Read more

Recent Controversies Involving Nassim Taleb, Part I

I've written about Nassim Taleb on earlier occasions in this blog. I'll let you do the search yourself, dear reader, for the full background. The short answer to the question "who is Taleb?" is this: he is a 57 year old man born in Lebanon, educated in France, who has been both a hedge fund manager and a derivatives trader. He retired from active participation from the financial world sometime between 2004 and 2006, and has been a full-time writer and provocateur ever since. Taleb's writings for the general public began where one might expect -- in the field where he had made his money -- and he explained certain financial issues to a broad audiences in a very dramatic non-technical way. Since then, he has widened has fields of study, writing about just about everything, applying the intellectual tools he honed in that earlier work. As you might have gather from the above, I respect Taleb, though I have sometimes been critical of him when my own writing ab...
4 comments
Read more